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Abstract: 
Examined the effects of methylphenidate (MPH) on the self-report ratings of 24 children with 
Attention Deficit Hyperactivity Disorder (ADHD). Children provided ratings of ADHD 
symptoms, side-effects, and self-esteem in a double-blind, placebo-controlled evaluation of three 
MPH doses (.16 mg//g, 
.29
 mg//g,
 .42
 mg//g). Mothers and teachers completed ratings of ADHD 
symptoms and side-effects. Children reported significant improvements in ADHD symptoms 
with medication in an analogous fashion to parent and teacher ratings. Regardless of dose, 
children reported some side-effects to be more severe than did parents or teachers. Children 
reported marginally significant increases in side-effect severity with MPH vs. placebo whereas 
teachers reported significant reductions in the severity of side-effects with treatment. The low 
dose led to significant improvements in children’s behavioral self-concept compared to placebo, 
although most children showed no overall change in self-concept. These results highlight the 
importance of children’s perceptions of MPH treatment for research and clinical purposes. 
 
Article: 
Methylphenidate (MPH) is the most widely used  treatment for children and adolescents with  
Attention Deficit Hyperactivity Disorder or  ADHD (Barkley, 1990; Conners & Wells, 1986). 
The positive effects of MPH on attention and social behavior have been demonstrated through 
teacher ratings (e.g., Pelham & Hoza, 1987), parent report (e.g., Barkley, Fischer, Newby, & 
Breen, 1988), direct observation of classroom behavior (e.g., Rapport, DuPaul, Stoner, & Jones, 
1986), and clinic-based tests of attention and impulse control (e.g., Douglas, Barr, O’Neill, & 
Britton, 1986). Very few investigations of MPH effects have included ratings completed by the 
children themselves presumably due to: (a) concerns about the reliability and validity of self-  
report data of ADHD symptoms obtained from this population (e.g., Landau, Milich, & Widiger, 
1991); (b) low agreement between self-report and behavior ratings of ADHD symptoms 
completed by parents and teachers (e.g., Loeber, Green, Lahey, & Stouthamer-Loeber, 1991) and 
(c) the salience of overt behavior concerns associated with the disorder (Hoza, Pelham, Milich, 
Pillow, & McBride, 1993). Alternatively, a number of empirical studies (e.g., Edelbroc/, Costello, 
Dulcan, Conover, & Kalas, 1986; Herjanic & ReiCh, 1982) have suggested that children may be 
better reporters of internalizing symptoms than are parents and teachers. Given that some of the 
possible side-effects of MPH include private events (e.g., anxiety, physical symptoms), it may be 
important to incorporate self-report data in a comprehensive evaluation of medication effects. 
 
Three previous studies have included self-report ratings of performance in determining MPH 
effects. Milich, Licht, Murphy, and Pelham (1989) had 26 boys with ADHD between the ages of 
7 to 11 years old evaluate their performance on a continuous performance test (CPT) when 
receiving either placebo or .3 mg/kg MPH in a double-blind cross
-
over design. They found that 
there was a high correlation between self-evaluation and the quality of CPT performance when 
the boys were medicated but not when they were receiving placebo. 
 
Whalen, Henker, Hinshaw, Heller, and Huber- Dressler (1991) found that self-evaluations of 
performance varied not only as a function of medication status but also with respect to whether 
children were told that they had received a placebo or active medication. In fact, boys who took 
placebo actually rated their computer task performance higher when they were told that they had 
received medication then when they were told that they had received a placebo. 
 
Pelham and colleagues (1992) conducted two experiments that included self-reports of behavior 
and effort. In the first experiment, 28 boys with ADHD between the ages of 7 to 11 years old 
received a low (either .15 or .3 mg/kg) and high (.3 or .6 mg/kg) dose of MPH in a double-blind, 
placebo-controlled design. At the end of each day, children were asked to complete a brief rating 
scale regarding their behavior, effort, attributions for performance, mood, and the degree to 
which they liked themselves. When receiving MPH, boys gave themselves higher behavior and 
effort ratings than during the placebo days. No significant differences between doses were 
reported. An additional 38 boys with ADHD between the ages of 7 to 13 years old participated in 
the second experiment. A double-blind crossover design was used wherein subjects received 
either no pill, placebo, or .3 mg/kg MPH each day. As in the first experiment, boys were more 
likely to report that they tried hard, had a good day, followed rules better, had fewer time-outs, 
and were more compliant when receiving MPH than during placebo days. 
 
The results of these investigations indicate that children with ADHD may reliably report 
behavior changes due to MPH treatment, although these reports may vary as a function of how 
they have been informed about their treatment status. Unfortunately, conclusions based on these 
results are limited by several factors including that: (a) subjects judged behavior change on a 
specific clinic task or at a global level only (e.g., good day vs. bad day); (b) children received 
both MPH and behavioral treatment contemporaneously; and (c) no between-dose analyses were 
reported. Importantly, no previous study has examined MPH effects on self-report of specific 
ADHD symptoms. 
 
Self-report data also may be important in determining the side-effects of MPH treatment. 
Surprisingly, only one study has systematically examined the possible side- effects of MPH in 
the context of a double-blind, placebo- controlled evaluation. Barkley, McMurray, Edelbrock, 
and Robbins (1990) obtained parent and teacher ratings of side-effects for 83 children with 
ADHD between the ages of 5 to 13 years old. Children received placebo, .3 mg/kg, and .5 mg/kg 
MPH in a crossover design. Parents reported a significant increase in four of 17 side- effects (i.e., 
insomnia, decreased appetite, stomachaches, and headaches) as a function of one or both doses 
of MPH. Teachers rated side-effects to be highest during the placebo condition. No self-report 
ratings were obtained. Thus, there may be important differences between parents and teachers in 
the observations of side-effects and it is unknown whether self-report data would highlight 
additional side-effects beyond those reported by parents and teachers. 
 
Self-report of medication effects may be important due to concerns that diminished self-esteem 
could be an emanative effect of MPH (Henker & Whalen, 1980; Whalen et al., 1991) and 
because lower than average self- esteem is a frequently encountered outcome for adolescents and 
adults with a childhood history of ADHD (e.g., Hechtman, Weiss, & Perlman, 1980; 
Slomkowski, Klein, & Mannuzza, 1995). Equivocal results have been obtained by two recent 
studies that have specifically examined the effects of MPH on self-esteem ratings. Pelham et al. 
(1992) found that boys treated with MPH reported liking themselves to a significantly greater 
degree when on medication than when receiving placebo. A trend toward the same findings was 
obtained with a separate sample of boys with ADHD treated with a low dose of MPH. 
Unfortunately, only a single item of self-esteem was included in these two experiments. Ialongo, 
Lopez, Horn, Pascoe, and Greenberg (1994) used a more comprehensive measure of self-esteem 
(i.e., the Self- Perception Profile for Children [SPPC]; Harter, 1985) in their study of MPH 
effects. A between-group design was used wherein 48 subjects with ADHD were randomly 
assigned to placebo, .4 mg/kg ,, or .8 mg/kg of stimulant medication. No significant pre-post 
changes over a 14- week period were obtained on any of the SPPC scales or for the Global Self-
Worth score. These results were limited by the use of a between-group design thereby obscuring 
differences in self-esteem between placebo and active medication within individuals. Also, it is 
unclear how these results can be generalized to children treated with MPH as a variety of 
stimulants were used in this investigation. 
 
The effects of MPH on self-report data obtained from children with ADHD are virtually 
unknown. First, no previous study has examined MPH effects on self-report of specific ADHD 
symptoms. Thus, it is unclear whether treated children represent a viable source of information 
about drug response. Second, the between-dose effects of MPH on self-report of side-effects 
have not been examined. There may be important differences among parents, teachers, and 
children regarding the presence or absence of medication side-effects. Finally, concerns have 
been raised about possible detrimental effects of MPH on self-esteem. Yet this phenomenon has 
not been examined using psychometrically sound measures of self- concept in the context of a 
crossover design. 
 
The purpose of the present study was to examine the effects of three doses of MPH on the self-
report ratings of a sample of children with ADHD. Three specific questions were posed: (a) Are 
children sensitive to changes in ADHD symptoms as a function of MPH? (b) Do ratings of side-
effects vary across dose and across sources of information (i.e., children, parents, teachers)? and 
(c) What are the acute effects of different doses of MPH on self-esteem ratings? These questions 
were investigated in the context of a double-blind, placebo-controlled crossover design using 
multiple measures of drug response. Based on prior research, it was hypothesized that: (a) 
children would report significantly fewer symptoms of ADHD with MPH treatment, (b) side-
effects would be reported to occur more frequently and to be more severe at the higher MPH 
doses, (c) parents would report more side-effects than teachers, and (d) MPH would have 
positive effects on children’s self-esteem. 
 
METHOD 
Participants 
Participants were 24 children (19 boys, 5 girls) between the ages of 9 and 15 years old (M == 
11.09, SD = 1.7) who met the following criteria: 
 
a) Parent and/or teacher referral to an outpatient ADHD clinic due to reported problems 
with inattention, impulsivity, and/or overactivity; 
b) Parent interview (from Barkley, 1990) indicating that the child met DSM-III-R 
(American Psychiatric Association, 1987) criteria for ADHD; 
c) Independent diagnosis of ADHD by psychologist and pediatrician using DSM-III-R 
criteria for ADHD; 
d) Parent or teacher ratings on the Attention Problem scale of the Child Behavior Checklist 
(Achenbach, 1991 resulting in a T-score of 65 or greater (i.e., 1.5 SDs above the mean); 
e) At least nine years old and able to read self-report questionnaires independently; 
f) No evidence of mental retardation, gross sensory o motor disabilities, seizure disorder, 
autism, psychosis, tic disorders or Tourette’s syndrome, or significant cardiac problems; 
g) Not currently receiving psychotropic medication. 
 
Children were primarily from lower middle class and middle class families. All were CauCasian. 
Five children received a diagnosis of Oppositional Defiant Disorder while an additional two 
subjects were diagnosed with Conduct Disorder. All parents of subjects signed a written 
informed consent statement agreeing to allow participation in this medication protocol. 
 
Procedures 
Children were consecutive referrals during the 1991-92 school year to a stimulant medication 
evaluation service jointly administered by the Psychiatry and Pediatrics departments of a 
university-affiliated hospital located in an urban setting in the northeastern U.S. Initially, each 
child was independently diagnosed as having ADHD by both a clinical or school psychologist 
and a pediatrician. A stimulant medication evaluation was recommended by both practitioners 
based on initial evaluation measures including parent interview, teacher and parent ratings, 
diagnostic interview with the child, and clinic analog observations of attention and behavior 
control. Approximately 40 percent of the patients seen for an initial evaluation were referred for 
a stimulant medication evaluation indicating that these children were exhibiting relatively severe 
symptoms of ADHD. 
 
All children then participated in a double-blind, placebo-controlled crossover design in which 
each subject was assessed when receiving placebo, low dose (M = .16 mg/kg; SD = .08), 
moderate dose (M = .29 mg/kg; SD = .11), and high dose (M = .42 mg/kg; SD = .14) of MPH 
given twice daily at morning and noon. Medication was prescribed in 5-mg increments with the 
dose range determined by the age of the child. Children under the age of 12 years old received 5 
mg, 10 mg, and 15 mg, while older participants were prescribed 10 mg, 15 mg, and 20 mg. MPH 
was dispensed in fixed doses as opposed to weight-adjusted doses given that body weight 
has not been found to be a significant correlate of stimulant effects (e.g., Rapport, DuPaul, & 
Kelly, 1989). Each medication condition lasted seven days with children being randomly 
assigned to one of six possible orders of MPH dosage wherein the high dose was never designat-
ed as the initial active medication condition. The medication was prepared by the hospital 
pharmacy in increments of 5 mg and packaged within opaque gelatin capsules. Unused capsules 
were returned to the clinic each week as a check on adherence to the medication schedule. No 
participant was removed from the investigation due to noncompliance (i.e., more than one day of 
failure to administer medication as scheduled). The participants as well as their parents, teachers, 
and the research assistant in charge of collecting data were blind to the order of medication. 
 
At the end of each dosage condition, participants met with the research assistant to complete a 
packet of self- report ratings. These questionnaires were completed independently by each 
participant; however, they were able to ask questions to clarify questionnaire directions or 
understanding of items. Parents and teachers also completed a packet of ratings at the end of 
each dosage week. Parent ratings were completed during each weekly clinic visit, while teacher 
ratings were mailed to the clinic on a weekly basis. The research assistant collected any unused 
medication and provided the following week’s medication with instructions for administration at 
each weekly clinic visit. 
 
Dependent Measures 
Self-report ratings. Three questionnaires were completed by each participant during all phases 
of the study. First, subjects completed a rating scale consisting of the 14 DSM-III-R symptoms 
of ADHD.
1
 Each symptom was listed as a separate item with the frequency of each symptom 
rated on a 0 (not at all) to 3 (very much) Likert scale. Items on this measure were the same as 
items on the ADHD Rating Scale (DuPaul, 1991) completed by parents and teachers, exCept that 
they were written in the first person (e.g., Difficulty paying attention to my work). Subjects were 
told to rate the frequency of each symptom over the previous week (i.e., since the beginning of 
the current medication condition). A total score was calculated as well as determination of the 
number of symptoms endorsed as occurring pretty much or very much of the time. 
 
The second self-report questionnaire was the Piers- Harris Self-Concept Scale (Piers, 1984) 
which contains 80 items rated on a yes-no basis. The Piers-Harris yields a total score as well as 
scores for five subscales (Behavior, Intellectual Status, Physical Appearance, Anxiety, 
Popularity, and Happiness). T-scores were used in the present analyses. The Piers-Harris has 
been found to possess adequate levels of reliability and validity (Piers, 1984). 
 
Subjects completed a questionnaire listing the 17 most common side-effects of MPH (Barkley, 
1981; Barkley et al., 1990). The occurrence of each side-effect was rated on a Likert scale 
ranging from 0 (not a problem) to 9 (severe). The rating scale was labeled as a &dquo;Behavior 
Questionnaire&dquo; to disguise its intended use as a monitoring instrument for potential side-
effects. This measure, when completed by parents and teachers, has been found to be sensitive to 
MPH effects (Barkley et al., 1990). Two scores were used in the present investigation : number 
of side-effects rated as present and the mean severity rating. 
 
Parent ratings. Parents completed two questionnaires on a weekly basis. These included the 
ADHD Rating Scale (DuPaul, 1991) and a rating of potential medication side-effects (Barkley, 
1981). The ADHD Rating Scale contains 14 items directly reflecting the DSMIII-R symptoms of 
ADHD. The frequency of each item was rated on a 0 (not at all) to 3 (very much) Likert scale. 
Two scores were derived from the ADHD Rating Scale: total score and the number of items 
rated as occurring pretty much or very much of the time. This rating scale has been found to have 
adequate levels of reliability and validity (DuPaul, 1991) and to be sensitive to MPH effects 
(Barkley, DuPaul, & McMurray, 1991). The side-effects measure was identical to that completed 
by the children and reflected parent perceptions of the severity of 17 potential side-effects. 
 
Teacher ratings. Teachers completed two questionnaires including the ADHD Rating Scale and 
a rating of potential medication side-effects. The ADHD Rating Scale was identical to the 
questionnaire completed by parents, as described above. The rating of potential side- effects was 
identical to those questionnaires completed by the children and parents. 
 
RESULTS 
MPH and respondent (Child, parent, teacher) effects on two sets of dependent measures (i.e., 
ratings of ADHD symptoms and possible side-effects) were examined. In 
 
addition, MPH-induced changes in self-esteem ratings were investigated. Means and standard 
deviations for all dependent measures by respondent group and MPH dose are presented in Table 
1. 
 
MPH and Respondent Effects on ADHD Ratings 
Two separate 3 (Respondent) X 4 (MPH Dose) analyses of variance (ANOVA) with repeated 
measures across the latter factor were conducted. There was no significant interaction between 
Respondent and Dose. Significant main effects for Respondent (F (2, 69) = 10.24, p < .001) and 
MPH Dose (F (3, 207) = 9.84, p < .001) were obtained for Total Score on the ADHD Rating 
Scale. Post hoc Tukey comparison tests were conducted to examine specific between-respondent 
and between-dose differences. Self-report scores on the ADHD Rating Scale were significantly 
lower than either parent or teacher ratings (p < .01). All three active doses of MPH resulted in 
significantly lower scores (indicating improvement) on this 
 
 
measure relative to placebo (p < .01). Trend analyses indicated that the dose-response 
relationship was linear (F (1, 207) = 26.84, p < .001) with nonsignificant quadratic and cubic 
components. 
 
A second 3 X 4 ANOVA was conducted for the number of significant symptoms (i.e., items 
scored as occurring &dquo;pretty much&dquo; or &dquo;very much&dquo; of the time) on the 
ADHD Rating Scale. As was the case for Total Score, significant main effects for Respondent (F 
(2, 69) = 9.63, p < .001) and MPH Dose (F (3, 207) = 12.40, p < .001) were obtained. Children 
reported significantly fewer ADHD symptoms than did parents or teachers (p < .01). All three 
aCtive doses of MPH significantly reduced the number of symptoms relative to placebo (p < 
.01). Further, the high dose was associated with fewer symptoms than the low dose (p < .05). 
The dose-response relationship was significantly linear (F (1, 207) = 35.33, p < .001) with 
nonsignificant quadratic and cubic components. 
 
Although a significant Respondent X MPH Dose interaction was not obtained for either 
dependent measure, specific dose effects for children’s self-report were examined given the 
interest in determining whether self-report of ADHD symptoms was sensitive to MPH treatment. 
An ANOVA with repeated measures across Dose was conducted for each ADHD Rating Scale 
score with significant effects on the number of symptoms (F (3, 69) = 3.26, p < .05) and 
marginally significant effects for Total Score (F (3, 69) = 2.60, p < .10) obtained. The three 
active MPH doses led to reductions in the Total Score relative to placebo (p < .05). The linear 
component of the dose- response relationship was significant (F (1, 69) = 5.12, p < .01) with both 
the quadratic and cubic components being nonsignificant. 
 
MPH and Respondent Effects on Side-Effects 
Two separate 3 (Respondent) X 4 (MPH Dose) ANOVA’s with repeated measures across Dose 
were conducted for side-effects ratings. First, no significant main or interaction effects were 
obtained for the number of side-effects reported. A second 3 X 4 ANOVA revealed a significant 
interaction between Respondent and Dose for the mean severity of side-effects ratings (F (6, 
207) = 6.30, p < .01). Thus, three separate ANOVA’s with repeated measures across Dose were 
conducted for each of the Respondent groups. A significant Dose effect was obtained for the 
mean severity of teacher side-effects ratings (F (3, 207) _= 4.17, p < .01). All three MPH doses 
led to significant reductions in mean severity ratings relative to placebo (p < .01) with the highest 
dose associated with the lowest severity compared to the low and moderate doses (p < .01). The 
linear component of the dose-response relationship was significant (F (1, 207) = 10.50, p < .01) 
with quadratic and cubic components being nonsignificant. Marginally significant differences 
were obtained for self-report of side-effect mean severity (F (3, 207) = 2.47, p < .10). 
Interestingly, mean severity ratings were higher for active MPH conditions relative to placebo 
(see Fig. 1), although mean differences were only marginally 
 
 
significant. No significant Dose effect was obtained for parent ratings of mean severity (F (3, 
207) = 0.49, N.S.). 
 
In order to examine possible Respondent and/or MPH Dose effects on individual side-effects, a 
series of 3 X 4 VNOOV’s with repeated measures across Dose were conducted for scores on 
each of the 17 items of the side- effects rating scale. Means and standard deviations for each item 
as a function of MPH Dose and Respondent are displayed in Table 2. Main effects for Dose were 
obtained only for Bites Nails (F (3, 204) = 2.88, p < .05) and Tics/Nervous Movements (F (3, 
204) = 3.80, p < .05). Ratings for Bites Nails were significantly lower for the Moderate relative 
to the Low Dose (p < .05). Tics/Nervous Movements were rated as less severe during the 
Moderate and High Dose conditions relative to placebo (p < .05). Interestingly, no significant 
increases in severity ratings as a function of MPH were found for any of the side-effects items. 
 
Significant main effects for Respondent were obtained for six items including: Insomnia (F (2, 
67) == 9.15, p < .001), Stares/Daydreams (F (2, 67) == 3.22, p < .05), Appetite (F (2, 67) = 7.42, 
p < .01), Drowsiness (F (2, 66) = 7.83, p < .01), Euphoric/Unusually Happy (F (2, 67) == 35.90, 
p < .001), and Dizziness (F (2, 68) == 3.53, p < .05). More specifically, self-report ratings were 
significantly greater than teacher ratings for Insomnia (p < .01), Appetite (p < .01), Drowsiness 
(p < .05), and Euphoric/Unusually Happy (p < .01). Self-report ratings were also higher than 
parent ratings for Drowsiness (p < .01), Euphoric/Unusually Happy (p < .01), and Dizziness (p < 
.05). Parent ratings were significantly greater than teacher ratings for Insomnia (p < .01) while 
teacher ratings were higher than parent ratings for Stares/ Daydreams (p < .05). 
 
The only significant Respondent X MPH Dose interaction was obtained for Nightmares (F ( 6, 
204) = 2.41, p < .05) with subsequent analyses revealing a significant Dose effect for self-report 
only (F (3, 204) = 4.53, p < .01). Specifically, lower self-report ratings of Nightmares were 
obtained for the three MPH doses relative to placebo (p < .01). No significant effects of Dose 
were found for either parent or teacher ratings of this item. 
 
Although significant increases in side-effects as a function of MPH were not obtained at the 
group level of analysis, it is important to consider the number of individual children who were 
reported to experience side- effects at each dose. The proportion of the sample who received a 
rating of &dquo;1&dquo; or greater on each side-effect item was calculated as a function of 
Dose and Respondent. Chi-square analyses of changes in proportions as a function of Dose 
within each Respondent group were all nonsignificant (p > .05). 
 
MPH Effects on Self-Esteem Ratings 
A series of one-way ANOVA’s with repeated measures across MPH Dose were conducted for 
the Total Score and each of the six subscales of the Piers-Harris. A significant MPH effect was 
obtained for the Behavior subscale (F (3, 66) = 4.05, p < .05). The Low dose of MPH led to 
significant increases in the Behavior T-score (i.e., indicating improvement) relative to placebo (p 
< .05). No further between-dose differences were obtained. The linear (F (1, 66) = 4.02, p < .05) 
and quadratic (F (1, 66) = 4.71, p < .05) components of the dose-response relationship were both 
found to be significant, while the cubic component was not. A marginally significant MPH Dose 
effect was obtained for the Anxiety subscale (F (3, 66) = 2.45, p < .10) with higher scores 
(indicating less anxiety) evident for the three MPH conditions. No other significant effects for 
Dose were obtained. 
 
A final set of analyses was conducted to examine whether some individual subjects evidenced 
lower (or higher) self-esteem in association with MPH treatment. First, reliable change indices 
(RCI; Jacobsen & Truax, 1991) were calculated across Dose for the Piers-Harris Total Score and 
each subscale. Specifically, each individual’s placebo score was subtracted from his or her score 
at each MPH dose with the result divided by the standard error of the difference. Next, each 
score was Categorized as representing significant improvement (RC1 > 1.96), significant 
deterioration (RCI < -1.96), and no change (-1.96 < RCI < 1.96). In general, most children 
reported no change in self-esteem for all Piers-Harris scores across all three doses. A few 
children showed improvement in self-esteem as a function of MPH with only one or two 
participants evidencing deterioration in self-esteem ratings with treatment. To illustrate the gen-
eral pattern of results, the percentage of subjects who were categorized as evidencing significant 
improvement, significant deterioration, or no change on the Piers-Harris total score as a function 
of dose is displayed in Figure 2. 
 
DISCUSSION 
The present investigation provided several findings illuminating the effects of MPH on self-
report ratings of children with ADHD. First, although children reported significantly fewer 
symptoms of ADHD than did their parents or teachers, self-report ratings were sensitive to med-
ication effects. In fact, MPH led to a decrease in the number of ADHD symptoms in a similar 
fashion regardless of respondent. Second, there were significant differences among respondents 
regarding the mean severity of side- effects as a function of medication. Teachers reported that 
side-effects were less severe during active medication conditions than during placebo.  
 
Conversely, there was a trend for children to report side-effects that were more severe when 
receiving MPH than placebo. No significant findings were obtained with respect to parent ratings 
of side-effects. Further, regardless of MPH dose, children reported five of the 17 side-effects to 
be more severe than did parents or teachers. Finally, the low dose of MPH led to significant 
improvements in children’s behavioral self- concept relative to placebo, with a similar trend for 
self- report of anxiety. Interestingly, the low dose was reported by children to be optimal in terms 
of their behavioral self-concept and reduction of ADHD symptoms (see 
 
Table 1). Overall, however, most children reported no significant acute change in self-esteem at 
any dose with some reporting improvement and only one or two children indicating deterioration 
in self-concept. 
 
Several previous studies have found that children with ADHD can reliably report changes in 
their performance as a function of medication treatment. For example, in two separate 
experiments Conducted by Pelham et al. (1992), children’s ratings of behavior and effort were 
improved by MPH relative to placebo. No between-dose differences were evident. The results of 
the present study are consistent with these findings as children reported significantly fewer 
symptoms of ADHD during MPH vs. placebo conditions. Although the linear component of the 
dose-response relationship was significant, no significant between-dose differences in self-report 
ratings were obtained. Further, the findings of the present investigation go beyond those obtained 
in prior studies by showing that: (a) children with ADHD can reliably report MPH-induced 
changes in symptoms of the disorder not just in global ratings of behavior and effort, and (b) the 
relationship between dose and report of symptoms is similar to that found for parent and teacher 
ratings. Thus, even though children report fewer overall symptoms of ADHD than do parents and 
teachers, self-report data show the same relative change with treatment as do parent and teacher 
ratings. 
 
This is the first study to systematically examine differences in the report of medication side-
effects across parents, teachers, and children. Similar to the results of Barkley et al. (1990), 
teachers reported the most severe side-effects to occur during placebo conditions. Given that 
most teachers are unable to observe children when the most prominent side-effects are likely to 
occur (i.e., during mealtimes and at night), this may not be a surprising result. Further, it may be 
that reductions in ADHD symptoms (which typically are most prominent during the school day) 
associated with MPH may result in a positive halo that influences teacher side-effects ratings.  
 
The consistency of this finding across studies implies that one should not rely exclusively on 
teacher report when evaluating possible side-effects. Contrary to Barkley et al.’s (1990) results, 
parents in the present study did not report any change in the number or severity of side-effects as 
a function of MPH. Because the dose ranges employed in the two studies were relatively similar, 
the differences in findings are most likely due to the smaller sample size employed in this 
investigation relative to the Barkley et al. study, thus limiting power to detect between-dose 
differences. Nevertheless, the lack of significant findings for parent report is indicative of the 
heterogeneity of response to MPH across children (i.e., the experience of side-effects is not a 
universal phenomenon). 
 
In contrast to teacher ratings of side-effects, there was a trend for children to report more severe 
side-effects with MPH than during placebo conditions. Further, regardless of experimental 
condition, children reported more severe side-effects for five items relative to parent and teacher 
report. These side-effects included insomnia, appetite reduction, drowsiness, euphoria, and 
dizziness. 
 
In the case of at least three of these items (i.e., drowsiness, euphoria, and dizziness), these may 
represent feeling states that are not directly observable by parents and teachers. In addition, as 
noted above, teachers are not typically in position to evaluate insomnia or appetite reduction in 
students. It is important to point out that these differences between respondents in the report of 
individual side-effects were obtained as a main effect across both placebo and MPH conditions. 
As such, these findings could reflect general feelings of discomfort and irritability that may be 
associated with ADHD rather than medication-induced side-effects. Taken together, the dif-
ferences in side-effect reports across respondents indicates the importance of obtaining side-
effect data not only from parents and teachers but children as well. In particular, children may be 
more reliable reporters of MPH-induced changes in subjective feeling states than are parents and 
teachers; although this conclusion must be corroborated with further study employing a larger 
sample and a wider dose range. 
 
Only two previous investigations have examined stimulant medication effects on the self-esteem 
of children with ADHD. Pelham et al. (1992) found an increase in self-liking scores associated 
with MPH vs. placebo, while Ialongo et al. (1994) found no differences in self- concept ratings 
after 14 weeks of medication. The present results are consistent with Pelham et al.’s findings in 
that children’s behavioral conduct scores on the Piers- Harris were improved relative to placebo 
during the low dose condition. Alternatively, the present findings are also consistent with 
Ialongo et al.’s results as the high dose in our study (.4 mg/kg) corresponded to the low dose in 
their study. In both cases, this dose of stimulant medication did not lead to reliable changes in 
self-esteem ratings. It is difficult, however, to comparecompare findings with the Ialongo et al. 
study given that the latter utilized a between-group design, a variety of stimulant medications, 
and evaluated changes in self-esteem over a much longer time period. Perhaps the acute 
improvements in self-esteem found by our study and Pelham et al. (1992) are short-lived 
phenomena that dissipate with time. At the very least, it is reasonable to conclude based on these 
three studies that MPH exerts very little effect on self- esteem with reliable improvement or 
deterioration occurring in only a few cases. 
 
Conclusions based on the present findings are limited by several factors. First, the sample size 
may have diminished the power to detect MPH effects on key variables, especially analyses of 
side-effects ratings. Second, the mean of the high dose condition (i.e., .42 mg/kg) is more 
representative of a mild to moderate dose of MPH, thereby tempering the generality of these 
results to the higher range of doses prescribed in typical practice (i.e., up to .7 mg/kg). In 
particular, the use of a lower dose range may have attenuated findings with respect to the 
presence and severity of side-effects. Third, although minimal acute effects of MPH on self-
esteem were obtained, it is possible that more significant changes (either deterioration or 
improvement) in self-concept could occur with longer-term pharmacotherapy. A single week at 
each dose may not be sufficient to elicit significant alterations in self-esteem. In a related 
manner, the sensitivity of self-concept ratings to MPH treatment may have been reduced by the 
response (Yes-No) format and the psychometric limitations of the Piers-Harris. It is possible that 
more significant findings would have occurred if a three-point or five-point Likert scale was 
employed. Fourth, it is unclear whether differences between children and adults in the report of 
ADHD symptoms is representative of a positive illusory style by the children or due to a 
differentially strong placebo effeCt operating on children’s ratings. Unfortunately, baseline (off 
medication) ratings of ADHD symptoms were not available; thus, precluding investigation of 
this question. Finally, the obtained results are generalizable only to children with ADHD 
between nine and 15 years of age. The reliability and validity of self-report data from children 
younger than nine are unknown. 
 
Despite these limitations, the results of this investigation indicate that children’s self-report is 
useful to obtain in the context of evaluating the effects of stimulant medication. In fact, this is the 
first study to clearly demonstrate that children with ADHD report significant reductions in 
ADHD symptoms as a function of MPH in a fashion similar to parents and teachers. In addition, 
conclusions about the severity of side-effects can be affected by who is asked to report them. At 
least within the moderate dose range employed in this study, children were more likely to report 
side-effects than were parents and teachers. Thus, it is imperative that clinicians ask all three 
respondents about side-effects rather than relying on a single source of information (i.e., parents) 
which is the more typical practice. At the group level, MPH had minimal effect on self-esteem 
ratings; however, there were a few individuals who reported significant deterioration in self-
concept with treatment. Thus, it would be prudent to monitor children’s feelings about 
themselves during the dosage titration process and to investigate instances of significant 
decreases in these feelings attendant to changes in dosage. More definitive conclusions about the 
value of children’s self-report for evaluating medication effects would be possible by conducting 
investigations employing larger samples, longer-term assessment, and a wider dose range than 
was used in the present study. Given the popularity and effectiveness of MPH in the treatment of 
children with ADHD, it is imperative that children’s perceptions of medication effects be studied 
more extensively. 
 
NOTES 
1. A copy of the self-report questionnaire is available from the first author upon request. 
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